Development and Validation of a Gradient RP-HPLC Method for Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir in Combined Pharmaceutical Formulation
Journal of Pharma Insights and Research · 2025
DOI: 10.69613/0376xn95 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharma Insights and Research, 2025. Verfasst von Durga Bhavani Ippe und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A novel gradient reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for simultaneous estimation of three antiretroviral drugs - Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir in combined tablet formulation. The chromatographic separation was achieved on an Inertsil C18 column (150 mm × 4.6 mm, 5 μm) using a gradient mobile phase consisting of phosphate buffer (pH 3.5) and acetonitrile:methanol (50:50 v/v). The flow rate was maintained at 1.6 mL/min with UV detection at 260 nm and column temperature at 30°C. The retention times for Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir were 2.881, 7.813, and 8.633 minutes respectively. The method demonstrated linearity over concentration ranges of 75-225 μg/mL for Lamivudine and Tenofovir Disoproxil Fumarate, and 12-39 μg/mL for Dolutegravir with correlation coefficients >0.999. Method validation parameters including accuracy, precision, specificity, robustness, and system suitability met ICH guidelines. The limits of detection were 0.1, 0.1, and 0.18 μg/mL, while limits of quantification were 0.3, 0.3, and 0.55 μg/mL for Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir respectively. Recovery studies yielded mean recoveries of 100.30%, 100.17%, and 99.60% for the three drugs. The validated method was successfully applied for routine quality control analysis of pharmaceutical formulations containing these drugs in combination.
Zitieren
APA
Ippe, D. B., Pappula, N., & G, P. (2025). Development and Validation of a Gradient RP-HPLC Method for Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir in Combined Pharmaceutical Formulation. Journal of Pharma Insights and Research. https://doi.org/10.69613/0376xn95
Vancouver
Ippe DB, Pappula N, G P. Development and Validation of a Gradient RP-HPLC Method for Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir in Combined Pharmaceutical Formulation. Journal of Pharma Insights and Research. 2025. doi:10.69613/0376xn95
BibTeX
@article{Ippe2025,
author = {Ippe, Durga Bhavani and Pappula, Nagaraju and G, Poornima},
title = {Development and Validation of a Gradient RP-HPLC Method for Simultaneous Estimation of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir in Combined Pharmaceutical Formulation},
journal = {Journal of Pharma Insights and Research},
year = {2025},
doi = {10.69613/0376xn95}
}
EUVIMED